Turn Therapeutics to present at Stifel 2026 Virtual Immunology and Inflammation Forum

Turn Therapeutics Inc.

CEO Bradley Burnam and Dr. Stephen M. Hahn to present on September 23, 2026 at 1:30 PM ET.
Presentation covers atopic dermatitis program, including pruritus-focused stage 2 enrichment strategy.
Emerging findings across patient populations: moderate-severe baseline pruritus and lower EASI with high IGA.
Live webcast on company website; replay available for approximately six months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.